Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 116

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 116
---
 surgery, treatment using GelrinC does not produce fibrous cartilage, but instead has been shown to grow hyalin-like cartilage,
which is the autologous natural cartilage of the patient.

<div align='center'>71</div>

Competing Therapies for Cartilage Repair

Beyond microfracture surgery,
current commercial therapies for cartilage repair generally involve the use of autologous cells harvested from the patient’s own
healthy tissue. This approach has numerous disadvantages including:

| ● | The need for expensive                                                     
 cell expansion facilities and the requirement for two surgical procedures. |

| ● | The price for such autologous                             
 procedures is approximately $40,000 in the United States. |

| ● | There are also allogeneic                                                                                                             
 cartilage products (BioCartilage and Neo) sourced from cadavers, which, based on our experience, are not preferred by surgeons except 
 for in unique cases.                                                                                                                  |

Due to the complexity, source
and cost of alternatives, orthopedic surgeons with whom we have consulted have expressed a strong preference for a simple, ‘off-the-shelf’
product that can be delivered through a single open or minimally invasive approach. There is also another technology, CartiHeal’s
(acquired by Smith & Nephew in January 2024) Agili-C, which was approved by the FDA in March 2022, that utilizes pre-formed implants
that consist of a two layer plug, of which the lower layer is a mineral/coral material that has been shaped to be inserted into a hole
drilled into bone, which part is expected to assimilate with the bone, and the upper layer part is a scaffold intended to serve as a
growth host for the cartilage cells. This pre-formed implant requires special fitting and drilling into the bone and related cartilage
lesion and in order to accommodate the lower layer of the implant (the scaffold), the surgeon must drill down into the underlying bone
even though the bone is often healthy. It is worthwhile mentioning that a minute fraction of patients present themselves with bone involvement
while an overwhelming majority have only cartilage injuries.

Our Strategy

We aim to provide patients
with safe, effective, simple, lasting treatments that are cost effective. With our lead product, GelrinC, patients may be treated for
cartilage injuries in the knee with an off-the-shelf product by a short and simple procedure that is highly cost effective.

Our first priority is to
complete patient